Weekly round up from Life Sciences Industry.
Flex Pharma, Inc. (Nasdaq: FLKS) today announced that its stockholders approved all proposals relating to its planned merger with Salarius Pharmaceuticals, LLC at Flex Pharma’s special meeting of stockholders. Flex Pharma will file a Form 8-K to disclose detailed voting results for each proposal. Flex Pharma expects to complete the merger within the next week or two.
Date: July 15, 2019
Source: Business Wire
Sign up for DistilINFO e-Newsletters.
Quest Diagnostics to Sell India Diagnostics Business to Strand Life Sciences
Takeda’s $80 Billion Acquisition of Shire Hits Snag in Europe
Subway Reportedly Weighs Potential Sale That Might Top $10B
Women’s Health Platform Maven Clinic Scores $90M in Funding
Ethypharm to Acquire Altan Pharma, Entering the Spanish Market and Enhancing Its Critical Care Portfolio and R&D Pipeline
Zydus Lifesciences Passes FDA Inspection Successfully
OncoCyte Announces Definitive Agreement to Acquire Razor Genomics
AstraZeneca, Eko Collaborate to Advance Innovation Around Heart Failure